Adult‐onset Still's disease following <scp>mRNA</scp>‐1273 Moderna <scp>COVID</scp>‐19 vaccination: A case report

Iwata, Masahiro; Ogawa, Tatsuya; Anju, Keisuke; Okiyama, Naoko; Nomura, Toshifumi

doi:10.1002/cia2.12281

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All 22 patients with adult-onset stills disease (ASOD) had a fever as a presenting complaint [7,74,[87][88][89][90]92,95,99,118,119,159,171,186]. Although characteristic salmon-pink skin rashes were also a common presenting feature along with arthralgia/arthritis, it was a delayed presenting feature in five patients [74,[87][88][89]118].…”

Section: Adult-onset Stills Diseasementioning

confidence: 99%

“…While six patients only needed corticosteroids, fifteen (68%) patients required multiple DMARDs to treat their condition: six required anakinra [88,92,186], four required tocilizumab [7,74,186], and one required cyclophosphamide [92]. Four patients required methotrexate [7,95,119,171] and two required cyclosporin [186] as maintenance therapy. Among the patients with cardiac involvement, two had bilateral pleural and pericardial effusions [74,88].…”

Section: Adult-onset Stills Diseasementioning

confidence: 99%

See 1 more Smart Citation

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Nune,

Durkowski,

Pillay

et al. 2023

Vaccines

View full text Add to dashboard Cite

A comprehensive, up-to-date systematic review (SR) of the new-onset rheumatic immune-mediated inflammatory diseases (R-IMIDs) following COVID-19 vaccinations is lacking. Therefore, we investigated the demographics, management, and prognosis of new R-IMIDs in adults following SARS-CoV-2 vaccinations. A systematic literature search of Medline, Embase, Google Scholar, LitCovid, and Cochrane was conducted. We included any English-language study that reported new-onset R-IMID in adults following the post-COVID-19 vaccination. A total of 271 cases were reported from 39 countries between January 2021 and May 2023. The mean age of patients was 56 (range 18–90), and most were females (170, 62.5%). Most (153, 56.5%) received the Pfizer BioNTech COVID-19 vaccine. Nearly 50% of patients developed R-IMID after the second dose of the vaccine. Vasculitis was the most prevalent clinical presentation (86, 31.7%), followed by connective tissue disease (66, 24.3%). The mean duration between the vaccine’s ‘trigger’ dose and R-IMID was 11 days. Most (220, 81.2%) received corticosteroids; however, 42% (115) received DMARDs such as methotrexate, cyclophosphamide, tocilizumab, anakinra, IV immunoglobulins, plasma exchange, or rituximab. Complete remission was achieved in 75 patients (27.7%), and 137 (50.6%) improved following the treatment. Two patients died due to myositis. This SR highlights that SARS-CoV-2 vaccines may trigger R-IMID; however, further epidemiology studies are required.

show abstract

Section: Adult-onset Stills Diseasementioning

confidence: 99%

Section: Adult-onset Stills Diseasementioning

confidence: 99%

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Nune,

Durkowski,

Pillay

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…A total of 164 non‐injection‐site reactions in 161 patients have been reported in previous case reports and series 7–88 . Patients with systemic lupus erythematosus (SLE) and lupus erythematosus profundus (LEP) showed exacerbation of lupus eruptions after 2 weeks, and other AEs developed several months later.…”

Section: Resultsmentioning

confidence: 99%

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Baba,

Yamada,

Kanekura

2024

The Journal of Dermatology

View full text Add to dashboard Cite

In Japan, cutaneous adverse events (AEs) following the coronavirus disease 2019 (COVID‐19) vaccination have been frequently described; however, a larger case series and literature review are lacking. There is an urgent need for an extensive investigation of new cases and previous reports to provide a thorough body of information about post‐COVID‐19 immunization cutaneous AEs. We aimed to analyze patients with cutaneous AEs after COVID‐19 vaccination in our hospital and review previous studies of cutaneous AEs. We analyzed post‐COVID‐19 vaccination cutaneous AEs in our department, the Japanese Registry, and previous literature. We enrolled 30 patients with cutaneous post‐vaccination AEs in our department over 2 years (April 1, 2021, to March 31, 2023). We also confirmed cases registered in the Ministry of Health, Labor, and Welfare COVID‐19 vaccine side effect reporting system (February 17, 2021–March 12, 2023). A total of 587 records were retrieved and 93 articles were included for data extraction. A total of 28 non‐injection‐site cutaneous AEs and two injection‐site AEs were identified. Six (20.0%) patients developed new‐onset erythematous eruptions, and five (16.7%) patients developed urticaria. Pruritic eruption, eczema, shingles, and sweating symptoms have also been reported. In previous studies on non‐injection‐site cutaneous AEs, individuals who received the BNT162b2 vaccine were older than those who received mRNA‐1273 (P < 0.01). Cutaneous AEs were mostly nonsignificant and self‐limiting reactions; however, rare, severe, or life‐threatening AEs were also reported. Physicians should be aware of the various possible cutaneous AEs associated with the COVID‐19 vaccination.

show abstract

Celecoxib/elasomeran

2023

Reactions Weekly

View full text Add to dashboard Cite

Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report

Abstract: A 57‐year‐old woman who was inoculated with the second dose of the mRNA‐1273 Moderna COVID‐19 vaccine and then developed adult‐onset still’s disease as a result.

Cited by 3 publications

References 5 publications

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Celecoxib/elasomeran

Contact Info

Product

Resources

About